EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Systemic Immune-Inflammatory Index, Tumor-Infiltrating Lymphocytes, and Clinical Outcomes in Esophageal Squamous Cell Carcinoma Receiving Concurrent Chemoradiotherapy

Jun Yang, Jifang Zheng, Jianjian Qiu, Mengyan Zhang, Lingyun Liu, Zhiping Wang, Qunhao Zheng, Yanyan Liu, Mingqiu Chen iD, Jiancheng Li iD

Journal of Immunology Research · 16.05.2023 · 2023 · 1-12

DOI: 10.1155/2023/4275998 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Immunology Research, erschienen am 16.05.2023. Verfasst von Jun Yang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, No. 420 Fuma Road Jin'an District, F…. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Clinical Key Specialty Project Foundation, Fujian Provincial Clinical Research Center for Cancer Radiotherapy and Immunotherapy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Systemic inflammation may be involved in the entire cancer process as a promoter and is associated with antitumor immunity. The systemic immune-inflammation index (SII) has been shown to be a promising prognostic factor. However, the relationship between SII and tumor-infiltrating lymphocytes (TIL) have not been established in esophageal cancer (EC) patients receiving concurrent chemoradiotherapy (CCRT).

Methods

Retrospective analysis of 160 patients with EC was performed, peripheral blood cell counts were collected, and TIL concentration was assessed in H&E-stained sections. Correlations of SII and clinical outcomes with TIL were analyzed. Cox proportional hazard model and Kaplan–Meier method were used to perform survival outcomes.

Results

Compared with high SII, low SII had longer overall survival (OS) ( P = 0.036 , hazard ratio (HR) = 0.59) and progression-free survival (PFS) ( P = 0.041 , HR = 0.60). Low TIL showed worse OS ( P < 0.001 , HR = 2.42) and PFS ( P < 0.001 , HR = 3.05). In addition, research have shown that the distribution of SII, platelet-to-lymphocyte ratio, and neutrophil-to-lymphocyte ratio were negatively associated with the TIL state, while lymphocyte-to-monocyte ratio presented a positive correlation. Combination analysis observed that SIIlow + TILhigh had the best prognosis of all combinations, with a median OS and PFS of 36 and 22 months, respectively. The worst prognosis was identified as SIIhigh + TILlow, with a median OS and PFS of only 8 and 4 months.

Conclusion

SII and TIL as independent predictors of clinical outcomes in EC receiving CCRT. Furthermore, the predictive power of the two combinations is much higher than a single variable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal Squamous Cell CarcinomaEsophageal NeoplasmsHumansLymphocytes, Tumor-InfiltratingRetrospective StudiesLymphocytesPrognosisChemoradiotherapyInflammationNeutrophils

Autor:innen und Institutionen

  • Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, No. 420 Fuma Road Jin'an District, Fuzhou 350014, Fujian Province, China.
  • Clinical Oncology School of Fujian Medical University, No. 420 Fuma Road Jin'an District, Fuzhou 350014, Fujian Province, China.

ORCID-Profile: Mingqiu Chen, Jiancheng Li

Förderung

  • National Clinical Key Specialty Project Foundation
  • Fujian Provincial Clinical Research Center for Cancer Radiotherapy and Immunotherapy

Zitieren

APA

Yang, J., Zheng, J., Qiu, J., Zhang, M., Liu, L., Wang, Z., Zheng, Q., Liu, Y., Chen, M., & Li, J. (2023). Systemic Immune-Inflammatory Index, Tumor-Infiltrating Lymphocytes, and Clinical Outcomes in Esophageal Squamous Cell Carcinoma Receiving Concurrent Chemoradiotherapy. Journal of Immunology Research, 2023, 1-12. https://doi.org/10.1155/2023/4275998

Vancouver

Yang J, Zheng J, Qiu J, Zhang M, Liu L, Wang Z, et al. Systemic Immune-Inflammatory Index, Tumor-Infiltrating Lymphocytes, and Clinical Outcomes in Esophageal Squamous Cell Carcinoma Receiving Concurrent Chemoradiotherapy. Journal of Immunology Research. 2023;2023:1-12. doi:10.1155/2023/4275998

BibTeX
@article{Yang2023,
  author = {Yang, Jun and Zheng, Jifang and Qiu, Jianjian and Zhang, Mengyan and Liu, Lingyun and Wang, Zhiping and Zheng, Qunhao and Liu, Yanyan and Chen, Mingqiu and Li, Jiancheng},
  title = {Systemic Immune-Inflammatory Index, Tumor-Infiltrating Lymphocytes, and Clinical Outcomes in Esophageal Squamous Cell Carcinoma Receiving Concurrent Chemoradiotherapy},
  journal = {Journal of Immunology Research},
  year = {2023},
  volume = {2023},
  pages = {1--12},
  doi = {10.1155/2023/4275998}
}
Kostenlos starten →